Zydus to Enter Global Biologics CDMO Business Plans
Zydus Lifesciences Ltd. (including its subsidiaries/affiliates, hereafter referred to as 'Zydus) today announced its entry into the global biologics contract development and manufacturing organization (CDMO) business through its plan to acquire Agenus Inc.'s (Nasdaq: AGEN) U.S.-based biologics CMC facilities. This acquisition marks Zydus' strategic investment in U.S.-based manufacturing for biologics thereby adding a sustainable growth driver for the group. Agenus Inc. is a clinical-stage immuno-oncology company committed to developing immune therapies that effectively combat cancer. Under the terms of the agreement, Zydus will acquire two state-of-the-art biologics manufacturing facilities from Agenus in Emeryville and Berkeley, California (US) for an upfront consideration of US$75 million and contingent payment of US$50 million to be paid over three years subject to achievement of certain revenue milestone. This acquisition provides Zydus immediate access to advanced biologics manufacturing capabilities and establishes a key presence in California, a leading global biotechnology hub. This strategic move enables Zydus to leverage supply chain dynamics and a favourable geopolitical environment to expand its reach in the U.S. and globally. With this acquisition Zydus will now become a one stop solution provider across the entire development spectrum of biologics, right from pre-clinical to toxicology studies, clinical development and now manufacturing.Zydus' CDMO business will operate as an independent entity and will house the acquired manufacturing capabilities. The facilities come with an experienced professional team with strong capabilities and requisite industry expertise to deliver high-quality biologics development and manufacturing services to global biotech and pharmaceutical companies. As a part of transaction Zydus will become an exclusive contract manufacturer for Agenus and will provide manufacturing services for clinical and commercial supply of two identified Phase-3 ready immuno-oncology products, Botensilimab (BOT) and Balstilimab (BAL). Zydus will also have first right of negotiation to manufacture any of the future pipeline products developed by Agenus. Zydus intends to further expand the team and help create new jobs in the region and contribute to the local economy.Speaking on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd. said, "The acquisition will give Zydus a strategic foothold in the U.S. for biologics manufacturing in the global hub for biotech innovation, California. It will enhance our ability to partner with innovation-centric entities, advancing new products and prioritizing patient-centric solutions. This move strengthens our long-term biologics vision and positions us to better serve the evolving needs of the global biopharmaceutical industry."
The global biologics CDMO market is experiencing significant growth, driven by the increasing complexity of therapies, the rise of biologics in clinical pipelines, and a growing number of emerging biotech companies lacking internal manufacturing capabilities. According to market.us, the Global Biologics CDMO Market Size is expected to be worth around US$ 84.9 Billion by 2034, growing at a CAGR of 15.7% between 2025 to 2034. As demand surges for reliable, agile, and scalable partners, Zydus' entry into this space positions it to tap into significant long-term growth opportunities and support innovation across the global biopharmaceutical landscape.
About Zydus
Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs 27,000 people worldwide, including 1,400 scientists engaged in R&D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars. For more details visit: www.zyduslife.com.
About Agenus
Agenus Inc. is a clinical-stage immuno-oncology company committed to developing immune therapies that effectively combat cancer. Leveraging proprietary scientific platforms, the company's pipeline includes multiple checkpoint antibody candidates, vaccines, and cell therapies. Headquartered in Lexington, MA, Agenus operates globally, driving innovations to bring better cancer treatments to patients. For more details visit: www.agenusbio.com.
Forward-Looking Statements:
This press release contains forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks and uncertainties include, but are not limited to, the successful integration of the acquired business, market conditions, and other factors.
Sujatha Rajesh (Media Relations), Zydus Lifesciences Limited, sujatha.rajesh@zyduslife.com, +91-9974051180
Arvind Bothra (Investor Relations), Zydus Lifesciences Limited, arvind.bothra@zyduslife.com, +91-7045656895
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
9 hours ago
- Economic Times
Valuations High, Earnings Weak — Markets May Pause
Despite geopolitical tensions, global equity markets, including India's Nifty, have shown resilience. While domestic investor participation provides support, a significant breakout requires stronger earnings growth, currently facing tepid levels. India's robust macros and potential trade deal outcomes could drive future earnings recovery, particularly in the banking sector, though elevated valuations suggest patience is warranted. Tired of too many ads? Remove Ads What are the possibilities of a breakdown below 24500 or a breakout above 25500? Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads A big learning from stock market experience is that the market's long-term trend is largely predictable; but the short-term trend is almost impossible to predict. The long-term trend of the market is dictated by earnings; but in the short-term, many non-fundamental factors impact the market, rendering predictions almost interesting feature of the behavior of global equity markets this year has been their resilience despite serious geopolitical turbulence. Even wars didn't trigger any significant correction in markets . Markets climbed all walls of worries that emerged from the geopolitical turbulence in May and June. In the mother market US, S&P 500 and Nasdaq set many new records this year. This resilience of global equity markets has been reflecting in the performance of the Indian market, too. Nifty has been oscillating between 24500-25500 since often, than not, triggers for correction come from unexpected developments. That's the unknown area. An important event that can influence the market in the near-term is the outcome of the India-US trade negotiations . An interim trade deal is likely. The unknown element is the tariff rate that will be imposed on the tariff rate is lower than 20 percent, that would be a positive. If it is much lower at around 15 percent, the market would respond positively since that would place India in an advantageous position vis-à-vis our trading news on the tariff front can impact the market pulling Nifty below the recent support level of 24500. But a sharp and sustaining correction appears unlikely since domestic buying can lift the market.A strong pillar of support for the rally which took the Nifty from the COVID low of 7511 in March 2020 to the recent peak of 26277 in September 2024 has been the active participation from domestic the FII selling, the market rallied. The sustained rise in the numbers of unique investors, demat accounts and SIP accounts have been a pillar of support for the market. The continuous fund flows into equity and hybrid funds enabled fund managers to buy every dip in the market. This trend can continue, providing resilience to the a clear breakout above Nifty 25500, taking the index to higher levels needs fundamental support from earnings . This is the challenge which the market is facing now. After sharp spurts in earnings in FY21, FY22 and FY24, earnings growth turned tepid in FY25. For FY25 PAT growth was a pedestrian 5.6 percent for Nifty FY26 the present trend indicates only about 10 percent earnings growth for Nifty 50. This modest earnings growth potential cannot facilitate a sustained rally in the are expected to grow beginning from Q3 FY26. India's macros are strong – GDP growth is the best among large economies; fiscal deficit and current account deficit at 4.8 percent and 1 percent of GDP respectively are under control; forex reserves are ample at around $700 billion, CPI inflation (2.1percent in June) is well within RBI's Government provided big fiscal stimulus through massive personal income tax cuts in the 2025 Budget and the MPC has complemented the fiscal stimulus with a 50 bp rate cut and 100 bp CRR cut in the June policy meet. This provides the ideal setting for an earnings Trump's tariff tantrums and the uncertainty that has triggered has impacted all economies including India. International trade has been impacted and exports are sluggish. This is a drag on the economy in the near-term but stability is expected to return after the initial strong macros will soon start reflecting in corporate earnings. This is likely to happen starting from Q3 when the banking sector starts reporting superior earnings benefiting from the CRR cut. Hopefully, credit growth too will start picking up soon responding to lower interest valuations in India, coupled with tepid earnings growth, is not a favorable market construct that can trigger and sustain a rally in the market in the near-term. This is the time to remain patient for better times, which are not far away.(The author is Chief Investment Strategist, Geojit Financial Services : Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
Time of India
9 hours ago
- Time of India
Valuations High, Earnings Weak — Markets May Pause
A big learning from stock market experience is that the market's long-term trend is largely predictable; but the short-term trend is almost impossible to predict. The long-term trend of the market is dictated by earnings; but in the short-term, many non-fundamental factors impact the market, rendering predictions almost impossible. An interesting feature of the behavior of global equity markets this year has been their resilience despite serious geopolitical turbulence. Even wars didn't trigger any significant correction in markets. Markets climbed all walls of worries that emerged from the geopolitical turbulence in May and June. In the mother market US, S&P 500 and Nasdaq set many new records this year. This resilience of global equity markets has been reflecting in the performance of the Indian market, too. Nifty has been oscillating between 24500-25500 since mid-May. Explore courses from Top Institutes in Please select course: Select a Course Category Others Management Technology healthcare CXO Public Policy Artificial Intelligence Data Analytics Design Thinking Digital Marketing PGDM Data Science Data Science MCA Product Management Project Management Healthcare Degree Operations Management Finance Leadership others Cybersecurity MBA Skills you'll gain: Duration: 28 Weeks MICA CERT-MICA SBMPR Async India Starts on undefined Get Details Skills you'll gain: Duration: 9 months IIM Lucknow SEPO - IIML CHRO India Starts on undefined Get Details Skills you'll gain: Duration: 7 Months S P Jain Institute of Management and Research CERT-SPJIMR Exec Cert Prog in AI for Biz India Starts on undefined Get Details Skills you'll gain: Duration: 16 Weeks Indian School of Business CERT-ISB Transforming HR with Analytics & AI India Starts on undefined Get Details What are the possibilities of a breakdown below 24500 or a breakout above 25500? More often, than not, triggers for correction come from unexpected developments. That's the unknown area. An important event that can influence the market in the near-term is the outcome of the India-US trade negotiations . An interim trade deal is likely. The unknown element is the tariff rate that will be imposed on India. If the tariff rate is lower than 20 percent, that would be a positive. If it is much lower at around 15 percent, the market would respond positively since that would place India in an advantageous position vis-à-vis our trading competitors. Live Events Negative news on the tariff front can impact the market pulling Nifty below the recent support level of 24500. But a sharp and sustaining correction appears unlikely since domestic buying can lift the market. A strong pillar of support for the rally which took the Nifty from the COVID low of 7511 in March 2020 to the recent peak of 26277 in September 2024 has been the active participation from domestic investors. Despite the FII selling, the market rallied. The sustained rise in the numbers of unique investors, demat accounts and SIP accounts have been a pillar of support for the market. The continuous fund flows into equity and hybrid funds enabled fund managers to buy every dip in the market. This trend can continue, providing resilience to the market. However, a clear breakout above Nifty 25500, taking the index to higher levels needs fundamental support from earnings. This is the challenge which the market is facing now. After sharp spurts in earnings in FY21, FY22 and FY24, earnings growth turned tepid in FY25. For FY25 PAT growth was a pedestrian 5.6 percent for Nifty 500. For FY26 the present trend indicates only about 10 percent earnings growth for Nifty 50. This modest earnings growth potential cannot facilitate a sustained rally in the market. Earnings are expected to grow beginning from Q3 FY26. India's macros are strong – GDP growth is the best among large economies; fiscal deficit and current account deficit at 4.8 percent and 1 percent of GDP respectively are under control; forex reserves are ample at around $700 billion, CPI inflation (2.1percent in June) is well within RBI's target. The Government provided big fiscal stimulus through massive personal income tax cuts in the 2025 Budget and the MPC has complemented the fiscal stimulus with a 50 bp rate cut and 100 bp CRR cut in the June policy meet. This provides the ideal setting for an earnings recovery. President Trump's tariff tantrums and the uncertainty that has triggered has impacted all economies including India. International trade has been impacted and exports are sluggish. This is a drag on the economy in the near-term but stability is expected to return after the initial chaos. India's strong macros will soon start reflecting in corporate earnings. This is likely to happen starting from Q3 when the banking sector starts reporting superior earnings benefiting from the CRR cut. Hopefully, credit growth too will start picking up soon responding to lower interest rates. Elevated valuations in India, coupled with tepid earnings growth, is not a favorable market construct that can trigger and sustain a rally in the market in the near-term. This is the time to remain patient for better times, which are not far away. (The author is Chief Investment Strategist, Geojit Financial Services ) ( Disclaimer : Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times) ETMarkets WhatsApp channel )
News18
11 hours ago
- News18
Gold Rate Today, July 26: Yellow Metal Falls For 3rd Day
Last Updated: Gold Price Today, July 26: In Mumbai, the price of gold stands at Rs 91,600 per 10 grams for 22-carat and Rs 99,930 per 10 grams for 24-carat. Gold Prices Today, July 26. Gold, Silver Prices In India Today, July 26: Gold prices on Saturday fell for the third day in a row. In Mumbai, the price of gold stood at Rs 91,600 per 10 grams for 22-carat and Rs 99,930 per 10 grams for 24-carat. Silver declined by Rs 2,000 to Rs 1,16,000 per kg. The MCX remains closed on Saturdays and Sundays. What Is The Price Of 22kt, 24kt Gold Rates Today In India Across Key Cities On July 26? City 22K Gold (per 10gm) 24K Gold (per 10gm) Delhi Rs 91,750 Rs 1,00,080 Jaipur Rs 91,750 Rs 1,00,080 Ahmedabad Rs 91,650 Rs 99,980 Patna Rs 91,650 Rs 99,980 Mumbai Rs 91,600 Rs 99,930 Hyderabad Rs 91,600 Rs 99,930 Chennai Rs 91,600 Rs 99,930 Bengaluru Rs 91,600 Rs 99,930 Kolkata Rs 91,600 Rs 99,930 Global Cues For Gold US spot gold (comex) was down 1.12% at $3,392.50 per ounce on Friday. The European Union and the United States now appear to be heading towards a possible trade deal, according to EU diplomats, which would result in a broad 15% tariff on EU goods imported into the US, mirroring a framework agreement Washington struck with Japan. The S&P 500 and the Nasdaq notched record closing highs overnight as signs of easing global trade tensions lifted risk sentiment among investors. Offering respite to gold, the US dollar index was headed for its worst week in a month, making greenback-priced gold less expensive for other currency holders. Data showed US jobless claims unexpectedly fell last week, signalling a steady labour market despite sluggish hiring making it harder for the unemployed to find work. The Federal Reserve is also widely expected to leave rates unchanged at its July 29-30 meeting, but markets continue to price in a potential rate cut in September. What Factors Affect Gold Prices In India? view comments Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
